

WORKSHOP

EIGHTH WORKSHOP ON DRUGS PRICING

SCIENTIFIC BOARD
Pier Luigi Canonico, Claudio Jommi

ROME
19TH | 20TH SEPTEMBER 2022

web | www.maprovider.com

Under the auspices of:



web | www.maprovider.com

OBJECTIVE

The workshop, now in its eighth edition, is a multistakeholder working table to discuss issues related to the assessment, appraisal and pricing of medicines from a national and international perspective.

The 8th Edition addresses the following topics:

- The evolution of HTA assessments in the next future
- Pricing challenges in the near futures
- Early access and possible price implications
- Pricing negotiations of combination

SCIENTIFIC PROGRAM

Monday September 19th 2022

13:30 Registration

14:00 Introduction
Pier Luigi Canonico, Claudio Jommi



Session I – THE EVOLUTION OF HTA ASSESSMENTS IN THE NEXT FUTURE

Chairperson: **Pier Luigi Canonico**

14:15 European Regulation on health technology assessment (HTA)
Maria Grazia Evandri*

14:45 Current examples of shared HTA assessments at European level: EUnetHA
Alessandra Lo Scalzo*

15:15 The point of view of the Italian Medicines Agency
Giuseppe Traversa*

15:45 *Break*

16:15 Discussion: The implications of the Regulation
Marcello Cattani*, Maria Grazia Evandri*, Armando Genazzani*, Alessandra Lo Scalzo*, Francesco S. Mennini, Francesca Patarnello*, Anna Ponzianelli*, Giuseppe Traversa*, Dominique Van Doorne

18:00 Question time

18:30 Conclusions
Pier Luigi Canonico

SCIENTIFIC PROGRAM

Tuesday September 20th 2022



Session II – PRICING CHALLENGES IN THE NEAR FUTURE

Chairperson: **Claudio Jommi**

- 08:30 Early access in Europe: the French experience
Lise Alter*
- 08:50 Early access of medicines in Italy and its impact on price negotiation:
Focus on programs: **Patrizia Popoli***
Focus on pricing: **Giovanna Scroccaro***
- 09:40 Early Access: advantages and disadvantages from the industry perspective
Giovanni Giuliani
- 10:00 Post marketing data coming from registries and their impact on renegotiation of price and reimbursement contracts
Pier Luigi Russo*
- 10:20 Renegotiation of the price and reimbursement contracts: opportunities and challenges from the industry perspective
Roberta Rondena*
- 10:40 Question Time
- 11:20 Break

WORKSHOP

SCIENTIFIC PROGRAM

Tuesday September 20th 2022

11:50 Incremental therapeutic innovation and pricing

How is incremental therapeutic innovation awarded in the international context

Claudio Jommi*

The industry perspective

Farindustria representative*

The perspective of payers

Mauro Biffoni*

13:00 Question Time

18:30 Conclusions
Pier Luigi Canonico

web | www.maprovider.com

WORKSHOP

SCIENTIFIC BOARD

Prof. Pier Luigi Canonico

Professor of Pharmacology, Università del Piemonte Orientale

Prof. Claudio Jommi

Professor of Practice of Health Policy, SDA Bocconi School of Management

FACULTY

Maria Grazia Evandri

Innovation and Drug Strategy Sector at A.I.F.A and deputy to the Italian representative at Committee for Medicinal Products for Human Use (CHMP), EMA European Medicines Agency

Alessandra Lo Scalzo

HTA, Age.Na.S. - National Agency for Regional Health Services

Giuseppe Traversa

Drug strategy and economics area, AIFA Italian Medicines Agency

Marcello Cattani

Country Lead - President & Managing Director, Italy & Malta at Sanofi

Armando Genazzani

CHMP member, EMA European Medicines Agency, Director of Pharmaceutical Sciences Department and Professor of Pharmacology, Università Del Piemonte Orientale

Francesco S. Mennini

President of SITHA and Professor for Health Economics, Università Di Roma "Tor Vergata"

Francesca Patarnello

VP Market Access & Government Affairs at Astrazeneca

Anna Ponzianelli

Vice President of Institutional Activities at SIARV and Institutional Affairs Head at Novartis Italy

Dominique Van Doorne

President of EUPATI European Patients Academy on Therapeutic Innovation

Lise Alter

Assessment & Access to Innovation Director chez Haute Autorité de Santé

WORKSHOP

Patrizia Popoli

Head, National Centre For Drug Research And Evaluation at Istituto Superiore di Sanità

Giovanna Scroccaro

Director of the Pharmaceutical Organic, Prosthetic and Medical Devices Unit, Regione Veneto

Giovanni Giuliani

Integrated Access Chapter Lead at Roche

Pier Luigi Russo

Director of the Monitoring Registries Office and Ad Interim Director of the Economic Evaluations Office, AIFA

Roberta Rondena

Executive Director, Market Access & Government Affairs at Bristol Myers Squibb

Mauro Biffoni

Director of The Department of Oncology and Molecular Medicine (OMM) at Istituto Superiore Di Sanità (ISS)

web | www.maprovider.com



A ► PHARMALEX Company

Società soggetta a direzione e coordinamento da parte di Pharmalex GmbH



MA Provider srl
via Vincenzo Monti 3 - 20123 Milano
Tel +39 02 89096682
Fax +39 02 89098927
E-mail | pricing@maprovider.com
web | www.maprovider.com

web | www.maprovider.com